Niessl, Julia http://orcid.org/0000-0001-8852-1924
Baxter, Amy E.
Mendoza, Pilar
Jankovic, Mila
Cohen, Yehuda Z.
Butler, Allison L.
Lu, Ching-Lan
Dubé, Mathieu
Shimeliovich, Irina
Gruell, Henning
Klein, Florian http://orcid.org/0000-0003-1376-1792
Caskey, Marina
Nussenzweig, Michel C.
Kaufmann, Daniel E. http://orcid.org/0000-0003-4467-136X
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé
Gouvernement du Canada | Canadian Institutes of Health Research (15977, 15049, 152536, 152977)
U.S. Department of Health & Human Services | National Institutes of Health (AI144462, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, 1P30AI124414-01A1, AI126620, 1P30AI124414-01A1, 1P30AI124414-01A1, R01AI-129795, AI-144462)
Einstein-Rockefeller-CUNY Center for AIDS Research
Bill and Melinda Gates Foundation (OPP1092074, OPP1124068)
Article History
Received: 24 June 2019
Accepted: 19 December 2019
First Online: 3 February 2020
Competing interests
: There are patents on 3BNC117 (PTC/US2012/038400) and 10-1074 (PTC/US2013/065696) that list M.C.N. as an inventor. M.C.N. is a member of the Scientific Advisory Board of Frontier Bioscience. Gilead has the rights to develop the 3BNC117 and 10-1074 antibody combination for clinical use.
Free to read: This content has been made available to all.